JP2017537972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537972A5 JP2017537972A5 JP2017538182A JP2017538182A JP2017537972A5 JP 2017537972 A5 JP2017537972 A5 JP 2017537972A5 JP 2017538182 A JP2017538182 A JP 2017538182A JP 2017538182 A JP2017538182 A JP 2017538182A JP 2017537972 A5 JP2017537972 A5 JP 2017537972A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- seq
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004498 CCR4 Receptors Human genes 0.000 claims description 2
- 108010017317 CCR4 Receptors Proteins 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 102100031351 Galectin-9 Human genes 0.000 claims description 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100030704 Interleukin-21 Human genes 0.000 claims description 2
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims description 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000024386 fungal infectious disease Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060381P | 2014-10-06 | 2014-10-06 | |
| US62/060,381 | 2014-10-06 | ||
| PCT/US2015/054202 WO2016057488A1 (en) | 2014-10-06 | 2015-10-06 | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138331A Division JP7129449B2 (ja) | 2014-10-06 | 2020-08-19 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537972A JP2017537972A (ja) | 2017-12-21 |
| JP2017537972A5 true JP2017537972A5 (OSRAM) | 2018-11-15 |
| JP6795505B2 JP6795505B2 (ja) | 2020-12-02 |
Family
ID=54337425
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538182A Active JP6795505B2 (ja) | 2014-10-06 | 2015-10-06 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| JP2020138331A Active JP7129449B2 (ja) | 2014-10-06 | 2020-08-19 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| JP2022131610A Active JP7589204B2 (ja) | 2014-10-06 | 2022-08-22 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138331A Active JP7129449B2 (ja) | 2014-10-06 | 2020-08-19 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| JP2022131610A Active JP7589204B2 (ja) | 2014-10-06 | 2022-08-22 | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10675349B2 (OSRAM) |
| EP (2) | EP3204418B1 (OSRAM) |
| JP (3) | JP6795505B2 (OSRAM) |
| CN (2) | CN107250160B (OSRAM) |
| AU (2) | AU2015328273B2 (OSRAM) |
| CA (1) | CA2962949C (OSRAM) |
| WO (1) | WO2016057488A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204418B1 (en) * | 2014-10-06 | 2020-03-25 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| JP2018504894A (ja) | 2014-12-19 | 2018-02-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | キメラ抗原受容体およびその使用方法 |
| JP6956639B2 (ja) | 2015-05-01 | 2021-11-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| EP3508206A4 (en) * | 2016-09-01 | 2020-04-29 | Bebeachibuli, Romeo | Food factor-based formulation, products produced using said formulation and methods for producing same |
| CN120795163A (zh) | 2016-10-14 | 2025-10-17 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| AU2018360766B2 (en) | 2017-11-06 | 2024-09-19 | Rapt Therapeutics, Inc. | Anticancer agents |
| CN108250290B (zh) * | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
| AU2019235900B2 (en) | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| JP7277255B2 (ja) * | 2018-05-31 | 2023-05-18 | 佳寛 大矢 | インビトロでの制御性ｔ細胞の特異性評価方法 |
| EP3927731A4 (en) * | 2019-02-19 | 2022-12-28 | The Regents of the University of Colorado, a body corporate | BISPECIFIC IMMUNOTOXINS FOR TARGETING HUMAN CD25S-CCR4+ TUMORS AND REGULATORY T-CELLS |
| KR20210145254A (ko) * | 2019-03-29 | 2021-12-01 | 유니베르시태트 취리히 | 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제 |
| EP4549555A3 (en) * | 2019-05-24 | 2025-07-30 | City of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| EP3983447A4 (en) | 2019-06-14 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| CN111704668B (zh) * | 2020-06-27 | 2021-03-30 | 天津金域医学检验实验室有限公司 | 抗ccr4抗体及其在治疗癌症中的应用 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| GB8426467D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| CA2116107A1 (en) | 1991-09-05 | 1993-03-18 | George Y. Wu | Targeted delivery of poly-or oligonucleotides to cells |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6989145B2 (en) * | 2000-03-03 | 2006-01-24 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody and antibody fragment |
| JP2003208610A (ja) | 2002-01-16 | 2003-07-25 | Noritsu Koki Co Ltd | 画像処理装置、画像処理方法、画像処理プログラム、および画像処理プログラムを記録した記録媒体 |
| US20070172476A1 (en) * | 2005-07-28 | 2007-07-26 | Kyowa Hakko Kogyo Co., Ltd. | Method of treating B-cell neoplasms or Hodgkin's lymphoma |
| WO2009086514A1 (en) * | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| GB201020738D0 (en) * | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| HK1207655A1 (en) * | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
| EP3204418B1 (en) * | 2014-10-06 | 2020-03-25 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
-
2015
- 2015-10-06 EP EP15782195.0A patent/EP3204418B1/en active Active
- 2015-10-06 US US15/517,108 patent/US10675349B2/en active Active
- 2015-10-06 CN CN201580066273.9A patent/CN107250160B/zh active Active
- 2015-10-06 CA CA2962949A patent/CA2962949C/en active Active
- 2015-10-06 AU AU2015328273A patent/AU2015328273B2/en active Active
- 2015-10-06 WO PCT/US2015/054202 patent/WO2016057488A1/en not_active Ceased
- 2015-10-06 JP JP2017538182A patent/JP6795505B2/ja active Active
- 2015-10-06 CN CN202210046788.4A patent/CN114634571A/zh active Pending
- 2015-10-06 EP EP20153701.6A patent/EP3699196A1/en active Pending
-
2020
- 2020-06-02 US US16/890,429 patent/US11723973B2/en active Active
- 2020-08-19 JP JP2020138331A patent/JP7129449B2/ja active Active
- 2020-12-10 AU AU2020286302A patent/AU2020286302B2/en active Active
-
2022
- 2022-08-22 JP JP2022131610A patent/JP7589204B2/ja active Active
-
2023
- 2023-06-22 US US18/213,132 patent/US12337034B2/en active Active
-
2025
- 2025-05-20 US US19/213,611 patent/US20250339521A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537972A5 (OSRAM) | ||
| JP2020193210A5 (OSRAM) | ||
| JP2022159548A5 (OSRAM) | ||
| Liu et al. | Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy | |
| Kirtane et al. | Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead | |
| Ha et al. | Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody | |
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| Baysal et al. | The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies | |
| JP2020127426A5 (OSRAM) | ||
| JP2015517470A5 (OSRAM) | ||
| JP2020103301A5 (OSRAM) | ||
| JP2019513777A5 (OSRAM) | ||
| JP2020503891A5 (OSRAM) | ||
| JP2020517259A5 (OSRAM) | ||
| Boettcher et al. | Development of CAR T cell therapy in children—A comprehensive overview | |
| JP2018508483A5 (OSRAM) | ||
| JP2017531427A5 (OSRAM) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| US11352428B2 (en) | Modulation of immune response using BTLA agonist antibodies | |
| JP2015535691A5 (OSRAM) | ||
| JP2018517415A5 (OSRAM) | ||
| JP2018529327A5 (OSRAM) | ||
| JP2012254083A5 (OSRAM) | ||
| JPWO2019173324A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) |